Alnylam Stock Crashes Nearly 30% as Company Lowers Full-Year Revenue Outlook
Alnylam cuts 2026 Amvuttra sales guidance to $4.2B–$4.5B due to slower growth in second-line ATTR-CM demand.
/ 4 items
#ALNY↓
Wainua Trial Setback Sends Ionis Plunging and Drags Down AstraZeneca
AstraZeneca and Ionis’s Wainua missed its primary endpoint in the Phase 3 ATTR-CM trial, while competitors Alnylam and BridgeBio surged.
Alnylam Teams Up with ChatGPT Creator’s AI Company to Revolutionize RNAi Therapeutics
Alnylam Pharmaceuticals partners with AI startup Inceptive in a deal worth up to $2 billion to accelerate discovery of next-generation RNAi therapeutics using powerful AI models.
Billion-Dollar Hearts: Tenaya and Alnylam Join Forces to Target Genetic Causes of Cardiovascular Disease
Tenaya Therapeutics partners with Alnylam to discover new genetic targets for heart disease treatments, potentially earning up to $1.13 billion in milestones.